NASDAQ:ALPN - Alpine Immune Sciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.01 -0.19 (-3.65 %) (As of 10/21/2018 04:00 PM ET)Previous Close$5.01Today's Range$5.01 - $5.2952-Week Range$4.89 - $11.79Volume11,399 shsAverage Volume20,458 shsMarket Capitalization$69.37 millionP/E Ratio-4.18Dividend YieldN/ABeta0.54 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington. Receive ALPN News and Ratings via Email Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ALPN CUSIPN/A Webwww.nivalis.com Phone206-788-4545 Debt Debt-to-Equity Ratio0.05 Current Ratio20.99 Quick Ratio20.99 Price-To-Earnings Trailing P/E Ratio-4.18 Forward P/E Ratio-2.36 P/E GrowthN/A Sales & Book Value Annual Sales$1.73 million Price / Sales40.11 Cash FlowN/A Price / CashN/A Book Value$5.68 per share Price / Book0.88 Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-7,780,000.00 Net Margins-1,602.19% Return on Equity-26.00% Return on Assets-23.83% Miscellaneous Employees38 Outstanding Shares13,850,000Market Cap$69.37 million Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions What is Alpine Immune Sciences' stock symbol? Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN." How were Alpine Immune Sciences' earnings last quarter? Alpine Immune Sciences Inc (NASDAQ:ALPN) announced its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.13. The biotechnology company had revenue of $0.39 million for the quarter, compared to analyst estimates of $0.30 million. Alpine Immune Sciences had a negative return on equity of 26.00% and a negative net margin of 1,602.19%. View Alpine Immune Sciences' Earnings History. When is Alpine Immune Sciences' next earnings date? Alpine Immune Sciences is scheduled to release their next quarterly earnings announcement on Monday, November 12th 2018. View Earnings Estimates for Alpine Immune Sciences. What price target have analysts set for ALPN? 5 brokers have issued twelve-month target prices for Alpine Immune Sciences' shares. Their predictions range from $12.00 to $13.00. On average, they expect Alpine Immune Sciences' stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 155.5% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences. What is the consensus analysts' recommendation for Alpine Immune Sciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences. Who are some of Alpine Immune Sciences' key competitors? Some companies that are related to Alpine Immune Sciences include ProMetic Life Sciences (PFSCF), MEI Pharma (MEIP), Seres Therapeutics (MCRB), Axovant Sciences (AXON), Aratana Therapeutics (PETX), Aldeyra Therapeutics (ALDX), CELYAD SA/ADR (CYAD), Acer Therapeutics (ACER), Ardelyx (ARDX), Tyme Technologies (TYME), Arbutus Biopharma (ABUS), Syros Pharmaceuticals (SYRS), Ocular Therapeutix (OCUL), Kamada (KMDA) and Tocagen (TOCA). Who are Alpine Immune Sciences' key executives? Alpine Immune Sciences' management team includes the folowing people: Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 50)Dr. Stanford Peng M.D., Ph.D., Exec. VP of R&D and Chief Medical Officer (Age 47)Dr. Mark J. Litton, Pres & COO (Age 50)Mr. Paul Rickey, Sr. VP & CFO (Age 39)Dr. Kristine Swiderek Ph.D., Sr. VP of Research How do I buy shares of Alpine Immune Sciences? Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Alpine Immune Sciences' stock price today? One share of ALPN stock can currently be purchased for approximately $5.01. How big of a company is Alpine Immune Sciences? Alpine Immune Sciences has a market capitalization of $69.37 million and generates $1.73 million in revenue each year. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Alpine Immune Sciences employs 38 workers across the globe. What is Alpine Immune Sciences' official website? The official website for Alpine Immune Sciences is http://www.nivalis.com. How can I contact Alpine Immune Sciences? Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected] MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 238 (Vote Outperform)Underperform Votes: 235 (Vote Underperform)Total Votes: 473MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/21/2018 by MarketBeat.com StaffFeatured Article: What is the NASDAQ?